Elucido™ : An investment opportunity
Excluding chronic (non-acute) hemodialysis, it is estimated that there are between 32 and 40 million annual treatment days or procedures globally utilising extracorporeal blood lines that could benefit from SciLogica’s real-time sensors and technology.
This market is estimated to be worth $5.4 - $6.7 billion.
Our Elucido™ system, protected by a strong patent portfolio, is a technologically evolutionary real-time measuring platform with the potential to be integrated into ex-vivo, in-vivo, and interstitial applications to enable continuous monitoring of blood analytes.
Click here to contact us regarding investment opportunities.